GLOBUS MEDICAL, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
GLOBUS MEDICAL, INC. (GMED) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$28.98 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2020-05-07
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was -$28.98M.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was -$9.77M, a 1058.88% decline year-over-year.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-03-31 was $1.02M, a 97.44% decline year-over-year.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2017-03-31 was $39.83M.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $55.98M, a 167.45% increase from fiscal 2018.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was $20.93M, a 59.27% decline from fiscal 2017.
- GLOBUS MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2017 was $51.39M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2020-03-31 | -$28.98M 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $55.98M 10-K/A · filed 2020-03-02 | ||||
| 2019-09-30 | $26.44M 10-Q · filed 2019-11-06 | ||||
| 2019-06-30 | -$21.96M 10-Q · filed 2019-08-01 | ||||
| 2019-03-31 | -$9.77M 10-Q · filed 2020-05-07 | ||||
| 2018-12-31 | $20.93M 10-K/A · filed 2020-03-02 | ||||
| 2018-09-30 | $20.93M 10-K · filed 2020-02-20 | $26.48M 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $1.13M 10-Q · filed 2019-08-01 | ||||
| 2018-03-31 | $1.02M 10-Q · filed 2019-05-02 | ||||
| 2017-12-31 | $51.39M 10-K/A · filed 2020-03-02 | ||||
| 2017-09-30 | $22.80M 10-Q · filed 2018-11-08 | ||||
| 2017-06-30 | $21.79M 10-Q · filed 2018-08-02 | ||||
| 2017-03-31 | $39.83M 10-Q · filed 2018-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |